Prevention of Paclitaxel-Associated Neuropathy With Fingolimod: a Pilot Trial
This trial phase I studies how well fingolimod works in preventing chemotherapy-induced nerve pain (neuropathy) in patients with breast cancer who are taking paclitaxel. Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by paclitaxel.
• Ability to complete questionnaires by themselves or with assistance.
• Paclitaxel at a dose of 80 mg/m\^2 given every week for a scheduled course of 12 weeks for treating breast cancer.
• Life expectancy \>= 6 months.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1.
• Negative pregnancy test (serum or urine) done =\< 14 days prior to registration, for persons of childbearing potential only.
• Provide written informed consent.